AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: NBI). AcelRx's addition to the NBI will become effective prior to market open on Monday, December 24, 2018.
The NASDAQ Biotechnology Index (NBI) contains securities of NASDAQ-listed companies that meet certain eligibility criteria, and are classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals. These requirements include minimum market capitalization, and average daily trading volume. The index is re-ranked annually and serves as the basis for the iShares NASDAQ Biotechnology Index Fund.